Company

About

CharlestonPharma

CharlestonPharma

Charleston, South Carolina, United States

CharlestonPharma is a biopharmaceutical company that develops a lead IgG1 monoclonal antibody targeting nucleolin transporter on tumor cells to induce apoptosis and cell death in various cancer cell lines.

Clemson University

Clemson University

Anderson, South Carolina, US

Clemson University is a higher education institution that offers health, wellness, and fitness services.

COSCIENS Biopharma

COSCIENS Biopharma

Charleston, South Carolina, United States

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize On 8/6/24 Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Elastrin Therapeutics Inc.

Elastrin Therapeutics Inc.

Simpsonville, South Carolina, United States

Elastrin Therapeutics is a South Carolina-based biotech developing novel therapies to reverse cardiovascular disease. Its underlying technology was developed by Dr. Naren Vyavahare during the last 20 years at Clemson University, in collaboration with Dr. Charles Rice. Our team built a proprietary platform that targets and restores degraded elastin by removing the harmful calcification that stiffens arteries. The platform significantly improves the efficacy of drugs and eliminates side effects by combining particle design with elastin targeting.